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2Abstract
Cells can adapt to hypoxia through the activation of hypoxia-inducible factor-1 (HIF-
1), which in turn regulates the expression of hypoxia-responsive genes. Defects in 
hypoxic signalling have been suggested to underlie the degeneration of motoneurons 
in amyotrophic lateral sclerosis (ALS). We have recently identified mutations in the 
hypoxia-responsive gene angiogenin (ANG) in ALS patients, and have demonstrated 
that ANG is constitutively expressed in motoneurons. Here we show that although 
HIF-1α is sufficient and required to activate ANG during hypoxia, ANG expression 
does not change in a transgenic ALS mouse model or in sporadic ALS patients. 
Administration of recombinant ANG, or expression of wild-type ANG protected 
motoneurons and against hypoxic injury, while gene silencing of ANG significantly 
increased hypoxia-induced cell death. The previously reported ALS-associated ANG
mutations (Q12L, K17I, R31K, C39W, K40I, I46V) all demonstrated a reduced 
neuroprotective activity against hypoxic injury. Our data demonstrate that ANG plays 
an important role in endogenous protective pathways of motoneurons exposed to 
hypoxia, and suggest that loss-of-function rather than loss-of-expression of ANG is 
associated with ALS.  
Keywords: ALS, angiogenin, HIF-1α, hypoxia, motoneuron. 
Abbreviations: ALS, amyotrophic lateral sclerosis; ARE, adenylate/uridylate-rich 
element; ANG, angiogenin; BSA, bovine serum albumin; CSF, cerebrospinal fluid; 
DAPI, 4’,6 diamidino-2-phenylindole; DFO, deferoxamine; DMEM, Dulbecco’s 
modified Eagle’s medium; ECL, enhanced chemiluminescence; FBS, fetal bovine 
serum; flk-1/vegfr2, vascular endothelial growth factor receptor 2; HIF-1, hypoxia-
3inducible factor-1; HRE, hypoxic response element; HRP, horseradish peroxidase;
MAP-2, microtubule-associated protein 2; NeuN, neuronal nuclei; PBS, phosphate 
buffered saline; SMI-32, 200 kD neurofilament heavy antibody; SOD1, superoxide 
dismutase-1; TBS, tris buffered saline; VEGF, vascular endothelial growth factor. 
Introduction
Hypoxic exposure of cells or organisms induces an adaptive response to compensate 
for the energy imbalance to maintain cell function (1). The most well studied adaptive 
mechanism is the expression of a cohort of hypoxia-responsive genes through the 
activation of the hypoxia-inducible factor-1 (HIF-1) (2, 3). Hypoxia leads to the 
accumulation of the α subunit of HIF-1 (HIF-1α). Heterodimerization of HIF-1α with 
its partner HIF-1β results in the formation of the HIF-1 complex. It binds to the 
hypoxic response element (HRE) that is present in all HIF target genes described to 
date (5’-RCGTG-3’), and enhances their transcription. While hypoxic exposure 
quickly stabilizes HIF-1α protein, normoxic exposure leads to immediate degradation 
of HIF-1α through hydroxylation of proline residues with subsequent ubiquitination 
and proteosomal degradation (4). 
Angiogenin (ANG) is an evolutionary highly conserved 123-residue, 14.1 kDa 
member of the pancreatic ribonuclease A (RNaseA) superfamily. It is a potent inducer 
of neovascularization (5, 6, 7) and a hypoxia-inducible factor (8, 9, 10). We have 
recently reported 7 missense mutations in the ANG gene in 15 patients suffering from 
amyotrophic lateral sclerosis (ALS), 4 with familial and 11 with apparently ‘sporadic’ 
ALS, in 5 distinct populations (11). ALS is a progressive late-onset neurodegenerative 
disorder with a fatal outcome, characterised by relatively selective motoneuron loss in 
4the spinal cord, brain stem and motor cortex, resulting in progressive paralysis and 
death (12).
A role for hypoxia-responsive genes in the pathogenesis of ALS was first suggested 
by the finding that mice with deletions in the HRE of the vascular endothelial growth 
factor (vegf) gene develop an ALS-like disease of adult-onset motoneuron 
degeneration and paralysis (13). Furthermore, VEGF delivery protected motoneurons 
from degeneration in both in vitro and in vivo models of ALS (14, 15).  However, 
mutations in VEGF or indeed genes involved in HIF signalling have not been 
identified so far in ALS patients (16).
The present study was therefore conducted to explore whether ANG is capable of 
protecting motoneurons against hypoxic injury or is required for their survival under 
hypoxic conditions, and to determine whether changes in ANG expression can be 
detected during ALS-associated motoneuron degeneration. Furthermore, we wished to 
explore the effect of reported ANG mutations on hypoxic injury. Our results suggest 
that ANG activity greatly influences motoneuron survival in response to hypoxia, and 
that a loss-of-function, rather than loss-of-expression of ANG plays an important role 
in motoneuron degeneration seen in ALS. 
Results
ANG is a hypoxia inducible factor in motoneurons 
We could recently demonstrate that ANG is expressed in motoneurons in vitro and in
vivo (11). To study the regulation of ANG in motoneurons under hypoxic conditions, 
primary mouse motoneuron cultures were exposed to atmospheric hypoxia of 10%, 
53% and 1% O2 for 24 hrs. Quantitative real-time PCR analysis of murine ang1 mRNA 
expression, the murine ortholog of human ANG (17), showed strong induction of this 
gene under hypoxic conditions of 10%, 3% and 1% O2 (Fig. 1A). In parallel we also 
examined vegf mRNA induction in these cultures. We noted a comparable vegf
mrRNA induction in the motoneurons exposed to atmospheric hypoxia of 10%, 3% 
and 1% O2 for 24 hrs (Fig. 1B). Moreover, a time course analysis of ang1 mRNA 
induction in motoneurons under conditions of 1% O2 over 24 hrs showed a time-
dependent increase in expression (Fig. 1C), in a similar fashion to vegf mRNA 
induction (Fig. 1D). In addition, Western blotting analysis confirmed the hypoxia-
induced increase in expression of ANG and VEGF proteins over time (Fig. 1E).
NSC34 is a hybrid cell line obtained from embryonic mouse spinal cord and mouse 
neuroblastoma cells with characteristics of primary motoneurons, including 
generation of action potentials and acetylcholine synthesis, storage and release (18). 
In another set of experiments, we transfected NSC34 cells with luciferase reporter 
constructs containing two mouse Ang1 promoters. Promoter 1 (Pr1) is universally 
active, while Promoter 2 (Pr2) is active only in hepatic cells in promoter assays in 
vitro (19) and which served as a negative control. Under hypoxic conditions of 1% O2
for 24 hrs, activity from Pr1 was increased more than 6-fold over empty vector alone 
(Fig. 1F). We obtained similar results when cells were exposed to the HIF-1α
stabilizer DFO, an iron chelator commonly used as a hypoxia-mimetic agent. In 
accordance with its hepatic specificity, Pr2 did not show any significant activity in 
NSC34 cells under hypoxia or DFO exposure (Fig. 1F).
Hypoxia-induced expression of ANG is associated with HIF-1α
6We next investigated whether HIF-1α stabilisation was sufficient to activate murine 
ang1. There was strong HIF-1α stabilization in primary motoneurons under hypoxic 
conditions, already detectable after 4 hrs at 1% O2 (Fig. 2A). Next, we expressed a 
constitutively active HIF-1α mutant in motoneurons and determined murine Ang1
expression. This HIF-1α double mutant is constitutively active due to mutated 
residues P564A and P402A, the proline residues targeted for hydroxylation and 
degradation in normoxia). We found that in motoneurons expressing constitutively 
active HIF-1α there was a significant increase in Ang1 mRNA fold induction even 
under normoxic conditions (Fig. 2B).
We next examined the effect of endogenous HIF-1α knockdown on ANG expression. 
HIF-1α knockdown was successfully achieved in HeLa cells using siRNA 
transfection (Fig. 2C). In cells transfected with siRNA targeting HIF-1α, hypoxia-
induced ANG mRNA transcription was significantly reduced when compared to cells 
transfected with a scrambled sequence (Fig. 2D). Together, these findings supported 
the hypothesis that HIF-1α stabilisation is sufficient and required for hypoxia-induced 
ANG gene activation.
ANG levels are not altered in motoneurons from SOD1G93A mice or ALS patients 
In a previous study we could detect significant ANG expression in motoneurons (11), 
a finding subsequently confirmed in other studies (20, 21). Indeed, immunostaining 
with antibodies to ANG in adult murine spinal cord cross sections showed strong 
expression in motoneurons, in particular in the cytosolic compartment, and a less 
intense staining in non-neuronal cells (Fig. 3A). However, the staining showed no 
significant differences between SOD1G93A and wild-type mice spinal cord samples 
7when examined at disease onset (90 days) and disease end stage. To further elucidate 
whether differences in ang1 expression can be detected in this murine ALS model, we 
next compared the induction of murine ang1 mRNA in lumbar spinal cord and motor 
cortex homogenates from SOD1G93A mice and their wild-type littermates (Figs. 3B-
C). Mice tissue samples were taken at 90 days of age (after symptom onset) or at 
disease end-stage (127 to 132 days). We did not observe any significant differences in 
Ang1 mRNA expression between wild-type and SOD1G93A spinal cord (Fig. 3B) or 
motor cortex samples (Fig. 3C). On the other hand, mRNA levels of both vegf and flk-
1/vegfr2 decreased significantly in spinal cord from SOD1G93A mice (Fig. 3D,F), in 
agreement with previous findings (22). 
Using post mortem spinal cord cross sections from ALS and non-ALS patients (see 
Supplementary Table 1 for case details), we also detected ANG expression in the 
cytoplasm of human anterior horn motoneurons (Fig. 4A). Semi-quantitative analysis 
of ANG staining intensity in the cell bodies of anterior horn motoneurons was 
assessed semi-quantitatively using a 4-point scale (23), and the results suggested no 
significant difference between ALS and non-ALS spinal cord samples (Fig. 4B).
Exogenously added ANG rescues cultured motoneurons from hypoxia-induced 
cell death
We next examined whether ANG is active against hypoxia-induced motoneuron death 
in vitro. Neuronal and motoneuron survivals were analyzed in primary motoneuron 
cultures after exposure to hypoxic conditions of 1% O2 for 24 hrs using the trypan 
blue exclusion method. Survivals of both motoneurons and the total neuronal pool 
decreased significantly following exposure to hypoxic conditions, such that only 45% 
8(± 3.0 S.E.M., p<0.05, n = 3) of MAP-2-immunopositive neurons and 36% (± 4.6 
S.E.M., p<0.05, n = 3) of peripherin-immunopositive motoneurons survived (Fig. 
5A), confirming the enhanced vulnerability of motoneurons in response to hypoxia 
(24, 25). To determine the neuroprotective effect of treatment with ANG, primary 
motoneuron cultures were exposed to hypoxic conditions of 1% O2 for 24 hrs and 
treated with either 100 ng/ml of human recombinant ANG protein, vehicle (BSA 
0.1%) or heat-denatured ANG. Following treatment, we examined motoneuron 
survival and found that addition of human recombinant ANG protein significantly 
increased motoneuron survival to 65% (± 2.9 S.E.M., p<0.05, n = 12), compared to 
only 35% (± 3.8 S.E.M., p<0.05, n = 12) in vehicle-treated cultures and 36% (± 4.2 
S.E.M., p<0.05, n = 12) in heat denatured ANG-treated cultures (Figs. 5B-C).
Knockdown of Ang1 enhances hypoxia-induced cell death
To explore the role of endogenous ang1 in the response of motoneurons to hypoxia, 
we investigated the effect of gene silencing on the survival of NSC34 cells, which 
have an increased endogenous resistance to hypoxia. Gene silencing was successfully 
achieved in NSC34 cells using siRNA and tested by means of PCR (Fig. 6A). In cells 
transfected with siRNA targeting ang1, hypoxia-induced injury significantly 
increased compared to mock-transfected cells or cells transfected with a scrambled 
sequence (Figs. 6B-D), suggesting that ang1 is required for maintaining motoneuron 
survival under hypoxic conditions.  
Neuroprotective effect of ANG against hypoxic injury is lost in the ALS-
associated mutants
9We next investigated the effects of the ALS-related ANG mutants K40I, R31K, K17I,
Q12L, I46V and C39W (11) on hypoxia-induced cell death. The ANG mutants were 
cloned into a mammalian expression vector also expressing the red fluorescent protein 
DsRed2 (pIRES2). Transfection of NSC34 cells with pIRES2-DsRed2 constructs 
containing any of these ANG mutations (Fig. 7A) did not reduce the levels of 
apoptosis in response to hypoxia when compared to empty vector-transfected cells, 
while wild-type ANG-overexpressing cells showed significantly reduced levels of 
apoptosis (Fig. 7B-C).
Discussion
In the present study we provide evidence that murine ang1 mRNA and protein is 
upregulated in motoneurons in response to hypoxia, and that HIF-1α is sufficient and 
required to upregulate ANG expression during hypoxia. An involvement of HIF-1α in 
ANG upregulation during hypoxia has so far not been directly demonstrated to our 
knowledge, but was expected owing to the existence of a consensus HRE (5’-
RCGTG-3’) in the murine ang1 and human ANG promoter. The expression of murine
ang1 in response to hypoxia in vitro mirrored that of another HIF-1α target gene, 
vegf.  We could also demonstrate a potent downregulation of vegf mRNA in the spinal 
cord of SOD1G93A transgenic mice in vivo, but interestingly we could not detect a 
concomitant decrease in murine ang1 expression. We also detected a down-regulation 
of flk-1 expression during disease progression. It has been suggested that an 
impairment to appropriately activate hypoxia-inducible factors like VEGF may be 
involved in disease progression in SOD1G93A mice (26) and sporadic ALS in humans
(27). Significant reductions in expression of VEGF and its major receptor, Flk-1 have 
been seen on motoneurons in the spinal cord of patients with ALS (22). It is possible 
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that the murine ang1 gene is constitutively expressed at higher levels and/or subject to 
positive regulation by other transcription factors. In addition to HIF1-α, other 
hypoxia-responsive transcription factors may also contribute to a differentially 
regulated gene expression in vivo (28). It is also possible that the effects observed in
vivo are more complex and subject to other regulatory events. It has been shown that 
mutant SOD1-linked ALS is associated with a destabilisation of vegf mRNA and with 
a downregulation of its expression (29). This negative effect was mediated through a 
specific interaction with the adenylate/uridylate-rich elements (AREs) of the 3’-
untranslated region of this gene. It is possible that the downregulation of vegf mRNA 
expression in mutant SOD1-expressing cells is indeed mediated via a specific 
inactivation at the level of the 3-UTR of this particular gene, and not due to a general 
inability to activate HIF1-α target genes.
Interestingly, we also found no evidence for differences in ANG levels in 
motoneurons of patients who suffered from the sporadic form of this disease. This 
finding is also confirmed by a recent study performed in CSF ANG levels in ALS 
patients (30), and by our previous study demonstrating no downregulation of ANG 
serum levels in ALS patients at diagnosis (31), but rather a small, but statistically 
significant up-regulation of serum ANG levels in ALS patients. The latter study also 
demonstrated that there was no correlation between serum ANG and VEGF levels. 
Although further studies may be required to elucidate changes in ANG levels in the 
spinal cord or CSF in ALS patients, the data from the present study and from  
previous reports, argue against a major role for ANG down-regulation in mutant 
SOD1-induced motoneuron degeneration and in sporadic ALS. 
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Our study rather suggests that motoneuron degeneration may be triggered by a loss-
of-function of the neuroprotective properties of the ANG gene. Motoneurons are 
particularly vulnerable to the inhibition of cellular bioenergetics that occurs during 
cellular hypoxia. In both in vivo and in vitro studies, motoneurons in particular have 
been shown to be more sensitive to short periods of oxygen deprivation than other 
spinal and central neurons (24, 25). In this study we provide evidence that ANG has 
significant neuroprotective activities on motoneurons exposed to hypoxic conditions 
in vitro. We also demonstrate that murine ang1 was required for the survival of 
motoneuron-like NSC34 cells under hypoxic conditions. Our findings therefore 
support the hypothesis that hypoxia-inducible factors such as ANG and VEGF may 
have direct effects on motoneuron survival (32). Finally, we demonstrate that the 
ANG mutations reported in our previous study (11) (K40I, Q12L, K17I, R31K and
C39W), including the I46V mutation (33) lack the neuroprotective activity against 
hypoxic exposure shown by wild-type ANG. These results are in accordance with a 
recent study, which showed that 3 of the identified ANG-ALS variants (Q12L, C39W, 
K40I) did not protect P19 embryonal carcinoma cells from hypoxic cell death (34). 
Based on the crystal structure of ANG, most of these point mutations affect 
functionally important residues, evolutionary highly conserved in ANG, Rnase A or 
both, and are involved in ANG nuclear import, nuclear localisation or ribonucleolytic 
activity (11, 35). Indeed, subsequent genetic and biochemical studies have identified 
further mutations in ANG in ALS patients (21, 33, 36), and have suggested that these 
may interfere with nuclear localisation, ribonucleolytic, and angiogenic activity in 
endothelial cells (20, 21).
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In summary, our results demonstrate that angiogenin plays a crucial role in the 
survival of motoneurons in response to hypoxia, and that loss-of-function rather than 
loss-of-expression of ANG may be involved in ALS.  
Materials and methods 
All experiments detailed here were carried out under licence from the Government of 
Ireland, Department of Health and Children and with ethical approval from the Royal 
College of Surgeons in Ireland Research Ethics Committee. 
Cell culture. Primary motoneuron cultures were prepared from E13 mouse embryos. 
Donor animals were terminally anaesthetized and embryos removed by hysterectomy. 
Spinal cord ventral horns were dissected from individual embryos, and the tissue was 
cut into <1 mm pieces and incubated for 10 min in 0.025% trypsin in Ham F10 
modified medium (Invitrogen, Paisley, Strathclyde, UK). The cells were then 
transferred into complete medium containing 0.4% BSA and 0.1 mg/ml DNAse1 
(both from Sigma-Aldrich, Tallaght, Dublin, Ireland), and gently dissociated. The cell 
suspension was spun and re-suspended in complete neurobasal medium. Cells were 
seeded onto poly-D,L-ornithine/laminin coated cell culture wells and maintained at 37 
ºC and 5% CO2.
Motoneuronal NSC34 cells were grown in high-glucose Dulbecco’s modified Eagle’s 
medium (DMEM, Sigma-Aldrich) containing 10% (v/v) heat-inactivated fetal bovine 
serum (FBS, Invitrogen) and 1% penicillin/streptomycin solution. HeLa cells were 
cultured in DMEM containing 10% FBS and 1% penicillin/streptomycin solution. 
Hypoxic conditions. Cells were placed in one of three hypoxia chambers (Coy 
Laboratory Products, Grass Lake, MI, USA) allowing the establishment of graded, 
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humidified, ambient, atmospheric hypoxia of 10%, 3%, and 1% O2, with 5% CO2 and 
a balance of N2 in all cases. Temperature was maintained at 37°C.  
Immunological stainings. Human spinal cord sections were obtained from the MRC 
Brain Bank, Kings College London, UK. Sections were deparaffinised in xylene 
before antigen retrieval was performed using citrate buffer (pH 6). Human or mouse 
spinal cord sections and cell cultures were immunostained using similar protocols. 
Sections or cultures were blocked (5% milk solution with 3% normal serum) for 1 hr 
at room temperature, incubated with primary antibody (ANG 1:500, Abcam, 
Cambridge, UK; NeuN 1:500, Chemicon, Harrow, UK; Peripherin 1:2,000, 
Chemicon; MAP-2 1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA; SMI-32 
1:500, Abcam) overnight at 4ºC, followed by secondary antibody (Rhodamine/ 
Fluorescein-conjugated 1:500, Jackson ImmunoResearch, Plymouth, PA, USA) at 
room temperature for 2 hrs, and then mounted in Vectastain containing 4’,6 
diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA, USA). 
Controls were prepared without either primary or secondary antibody, and no staining 
was observed. 
Semi-quantitative analysis of immunohistochemistry. The intensity of ANG staining in 
the cell bodies of anterior horn motoneurons from human spinal cord cross sections 
was assessed semi-quantitatively using a 4-point scale (23): zero = staining absent, + 
= weak, ++ = moderate, +++ = strong. Immunoreactivity was considered weak (+) if 
it was poorly apparent at low-power magnification, but identifiable using the high-
power objective. Moderate (++) and strong (+++) staining reactions were apparent at 
low power. Five fields (area = 0.125 mm2) were assessed in each anterior horn. The 
number of motoneurons in each staining category was then expressed as a proportion 
of the total number of motoneurons counted in order to control for variation in the 
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absolute number of motoneurons examined. Statistical analysis was assessed using the 
Fisher’s exact test.
Western blotting. Equal amounts of protein were separated by electrophoresis, and 
transferred to a nitrocellulose membrane followed by blocking for 1 hr (TBS 
containing 0.1% Tween, 3% skim milk). Membranes were then incubated in primary 
antibody to ANG (1:500, Abcam), VEGF (1:1,000, Abcam), murine HIF-1α (1:1,000, 
Biomol, Exeter, UK), human HIF-1α (1:500, BD Biosciences, Oxford, UK), DsRed 
protein (1:200, BD Biosciences Clontech) or ß-actin (1:2,500, Sigma-Aldrich) 
overnight at 4ºC. After washing, membranes were incubated with horseradish 
peroxidase (HRP)-conjugated secondary antibodies (1:5,000, Jackson 
ImmunoResearch) at room temperature for 2 hrs, followed by detection using ECL 
detection reagent (Amersham Biosciences, Buckinghamshire, UK). 
Analysis of mRNA expression. Total RNA was extracted from cell cultures using the 
RNeasy Mini Kit (Qiagen, Hilden, Germany), and from tissue homogenates using the 
TRIZOL Reagent (Invitrogen). First strand cDNA synthesis was performed according 
to manufacturers’ instruction using 2 µg Moloney murine Leukaemia virus reverse 
transcriptase (Invitrogen). Quantitative real-time PCR was performed using the 
LightCycler (Roche Diagnostics, Basel, Switzerland) and the QuantiTech SYBR 
Green PCR kit (Qiagen). Sense and antisense primers, respectively, were as follows: 
human ANG, 5’-GGGCGTTTTGTTGTTGGTCT-3’ ; 5’-
GCGCTTGTTGCCATGAATAA-3’. Human β-actin, 5’-
TCACCCACACTGTGCCCATCTACGA-3’ ; 5’-
CAGCGGAACCGCTCATTGCCAATGG-3’. Murine ang1, 5’-
TCCTGACTCAGCACCATGAC-3’ ; 5’-TCTGTAAGGGCTTCCATTCG-3’. 
Murine vegf, 5’-GTACCTCCACCATGCCAAGT-3’ ; 5’-
15
GCATTCACATCTGCTGTGCT-3’. Murine flk-1, 5’-
CAGCTTCCAAGTGGCTAAGG-3’ ; 5’-CAGAGCAACACACCGAAAGA-3’. 
Murine β-actin, 5’-AGGTGTGATGGTGGGAATGG-3’ ; 5’-
GGTTGGCCTTAGGGTTCAGG-3’. Each primer pair was tested with a logarithmic 
dilution of a cDNA mix to generate a linear standard curve, which was used to 
calculate the primer pair efficiency. The PCR reactions were performed in 20 µl 
volumes with the following parameters: 95°C for 15 min followed by 35 cycles of 
94°C for 20 s, 59°C for 20 s, 72°C for 20 s. The generation of specific PCR products 
was confirmed by melting curve analysis and gel electrophoresis. The data was 
analysed using the Lightcycler Software 4.0 with all samples normalized to β-actin.
All experiments were performed in triplicate. 
Cloning of ANG and site-directed mutagenesis. The full-length cDNA of human ANG
was amplified by PCR (sense primer: 5’-GGAGCCTGTGTTGGAAGAGA-3’; 
antisense primer: 5’-TGAATGTTGCCACCACTGTT-3’) and inserted into the PCR-
Blunt II-TOPO vector (Invitrogen). Point mutations were inserted in the ANG
sequence using the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, CA, USA). Sense and antisense primers for the different mutations were: K40I:
5’-GGCCTGACCTCACCCTGCATAGACATCAACACATTTATTC-3’ and 5’-
GAATAAATGTGTTGATGTCTATGCAGGGTGAGGTCAGGCC-3’. R31K: 5’-
GTGAAAGCATCATGAAGAGACGGGGCCTGAC-3’ and 5’- 
GTCAGGCCCCGTCTCTTCATGATGCTTTCAC-3’. K17I: 5’-
CAGCACTATGATGCCATACCACAGGGCCGGGATG-3’ and 5’-
CATCCCGGCCCTGTGGTATGGCATCATAGTGCTG-3’. Q12L: 5’-
CACACACTTCCTGACCCTGCACTATGATGCCAAAC-3’ and 5’-
GTTTGGCATCATAGTGCAGGGTCAGGAAGTGTGTG-3’. I46V: 5’-
16
CAAAGACATCAACACATTTGTTCATGGCAACAAGCGCAG-3’ and 5’-
CTGCGCTTGTTGCCATGAACAAATGTGTTGATGTCTTTG-3’. C39W: 5’-
CCTGACCTCACCCTGGAAAGACATCAACAC-3’ and 5’-
GTGTTGATGTCTTTCCAGGGTGAGGTCAGG-3’. Presence of the mutations was 
confirmed by sequencing. The ANG fragment was then subcloned into the pIRES2-
DsRed2 vector (BD Biosciences Clontech). 
Promoter reporter assays. NSC34 cells were plated at 75,000 cells per well in a 24-
well plate 24 hrs prior to transfection. Cells were then transiently cotransfected with 
0.3 µg per well of the pGL3-derived constructs (pGL3 Basic, vector only; pGL3-Pr1, 
Ang1 Pr1 promoter; pGL3-Pr2, Ang1 Pr2 promoter) and 0.025 µg per well of the 
phRL-TK control reporter (19). Transfections were carried out using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s recommendation, and 24 hrs after 
transfection cells were exposed to hypoxia (1% O2) or deferoxamine (DFO, Sigma-
Aldrich). The Dual-Luciferase Reporter Assay (Promega, Madison, WI, USA) was 
used to determine transcriptional activity of the reporter constructs according to 
manufacturer’s suggestions. The firefly luciferase (experimental promoter construct) 
activities of each of the experimental constructs were normalized to the Renilla 
luciferase (co-transfectant control promoter construct) activity. All experiments were 
performed in triplicate.  
HIF-1α overexpression. Primary motoneuron cultures were seeded in 6-well plates 
and transfected with either 2 µg per well of pcDNA3-HIF-1α wild-type, pcDNA3-
HIF-1α double mutant or pcDNA3 empty vector, as previously described (37). The 
double mutant form of HIF-1α is constitutively active due to mutations at both Pro-
564 and Pro-402 (the residues targeted for hydroxylation and degradation in 
normoxia). Cells were transfected using the Lipofectamine 2000 reagent in OptiMEM 
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medium (Invitrogen) according to the manufacturer’s instructions. Transfection was 
carried out for 24 hrs, changing then the medium to standard growth medium. After
24 hrs, cultures were harvested immediately for RNA extraction.   
siRNA transfection. For ang1 knockdown, NSC34 cells were plated on 24-well plates, 
grown to ∼50% confluence and transfected with 100 nM of predesigned siRNA to 
murine Ang1 (siGENOME-ON-TARGETplus, Dharmacon, Lafayette, CO, USA). For 
HIF-1α knockdown, HeLa cells were plated on 35mm plates, grown to ~50% 
confluence and transfected with 5 nM human specific HIF-1α siRNA (Dharmacon). 
Transfections were performed using Lipofectamine 2000 in antibiotic free media 
according to manufacturer’s instructions. As a control, the same concentration of non 
target siRNA (Dharmacon) was used for each transfection. All transfections were 
repeated in triplicate.
NSC34 transient transfection and cell survival. Cells were transfected with pIRES2-
DsRed2 plasmids using Lipofectamine 2000 and 24 hrs later exposed to hypoxia (1% 
O2) for 24 or 48 hrs. Cell survival in transfected cells (red fluorescence) was assessed 
according to nuclear morphology after staining with Hoechst 33258 (1 µg/ml, Sigma-
Aldrich). Hoechst staining was used to quantify only strongly condensed and/or 
highly fragmented nuclei, late and key hallmarks of apoptosis. All experiments were 
repeated in triplicate. 
Motoneuron viability. At the end of treatment cultures were incubated in trypan blue 
(Sigma-Aldrich) for 5 min, washed in PBS and fixed with 4% paraformaldehyde in 
0.1 M PBS. Fixed cells on coverslips were then immunostained with antibodies to the 
motoneuron-specific markers peripherin (Chemicon) or SMI-32 (Abcam). Only 
motoneurons stained with the specific marker and containing no trypan blue were 
considered viable and counted. 
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Figure legends 
Figure 1. ANG expression is induced under hypoxia in motoneurons. A-B, 
Quantitative real-time PCR analysis showing murine Ang1 (A) and VEGF (B)
transcription levels in primary motoneurons exposed to atmospheric hypoxia of 10%, 
3% and 1% O2 for 24 hrs (*P<0.05, mean ± S.E.M. from 3 independent experiments). 
C-D, Time course analysis of Ang1 (C) and VEGF (D) mRNA increase under 
exposure to 1% O2 (*P<0.05, mean ± S.E.M. from 3 independent experiments). E,
Representative Western blot analysis of ANG and VEGF protein levels after exposure 
of motoneurons to 1% O2. F, Luciferase reporter assays showing Ang1 promoter 
activity in NSC34 cells. Cell cultures were transfected with pGL3 reporter constructs 
containing Promoter 1 (Pr1) and Promoter 2 (Pr2) from mouse Ang1 and then exposed 
to hypoxia (1% O2) or deferoxamine (DFO, 100 µM) for 24 hrs. Values are 
normalized to pGL3 basic, which lacks a promoter (*P<0.01 vs control Pr1, mean ± 
S.E.M. from 3 independent experiments). 
Figure 2. Hypoxia induces ANG expression in a HIF-1α-dependent manner. A, 
Representative Western blot showing HIF-1α stabilization in motoneurons upon 
hypoxic exposure. B, Ang1 mRNA levels are increased in motoneurons 
overexpressing wild-type HIF-1α or constitutively active (CA) HIF-1α (mutated at 
the oxygen-dependent degradation residues Pro-564 and Pro-402). Cells were 
transfected for 24 hrs, changing then the medium to standard growth medium. After
24 hrs, cultures were harvested immediately for RNA extraction and quantitative real-
time PCR was carried out (*P<0.05 vs control untransfected cells, mean ± S.E.M. 
from 3 independent experiments). C, Representative Western blot showing effective 
silencing of HIF-1α following siRNA transfection in HeLa cells. D, Endogenous
24
HIF-1α knockdown by siRNA in HeLa cells significantly reduced hypoxia-induced 
ANG mRNA transcription (*P<0.01 vs scramble, mean ± S.E.M. from 3 independent 
experiments).  
Figure 3. ANG expression is not altered in motoneurons from SOD1G93A mice. A,
Immunostaining of adult spinal cord cross sections showing ANG expression in 
motoneurons from wild-type (left) and SOD1G93A mice (right, scale bar = 50 µm). B-
G, Quantitative real-time PCR analysis showing murine Ang1 (B-C), VEGF (D-E)
and Flk-1 (F-G) transcription levels in lumbar spinal cord (B, D, F) and motor cortex 
(C, E, G) homogenates from SOD1G93A mice and wild-type littermates (mean ± 
S.E.M., n = 9).
Figure 4. ANG expression is not altered in post mortem spinal cord samples from 
ALS patients. A, Immunostaining of human spinal cord cross sections from ALS and 
non-ALS patients showing ANG expression (red) in anterior horn motoneurons. 
(Scale bar = 50 µm). B, Immunohistochemistry quantitation. Intensity of ANG 
staining in the cell bodies of anterior horn motoneurons from human spinal cord cross 
sections was assessed using a 4-point scale: 0 = staining absent, + = weak, ++ = 
moderate, +++ = strong. P( ), proportion of anterior horn motoneurons showing 0, +, 
++, or +++ staining intensity. 
Figure 5. Hypoxia-induced cell death in motoneuron cultures can be alleviated 
by ANG. A, Direct counts of neuron survival (MAP-2-positive cells) and motoneuron 
survival (peripherin-positive cells) in primary ventral horn motoneuron cultures 
exposed to hypoxia (1% O2) for 24 hrs (*P<0.05 vs sister cultures at atmospheric 
25
oxygen, mean ± S.E.M. from 3 independent experiments). B, Direct counts of 
motoneuron survival (peripherin-positive cells) in primary motoneuron cultures 
exposed to hypoxia (1% O2) for 24 hrs. Cultures were treated with ANG (100 ng/ml), 
heat denatured ANG (100 ng/ml) or vehicle (*P<0.05 vs vehicle or denatured ANG-
treated cultures, mean ± S.E.M. from 3 independent experiments). C, Representative 
photomicrographs of SMI-32- (green, a-c, g-i), peripherin (red, d-f, j-l) and DAPI- 
(blue) immunostained primary motoneuron cultures. Cultures were treated with ANG 
(100 ng/ml), denatured ANG (100 ng/ml) or vehicle and exposed to hypoxia (1% O2,
g-l) for 24 hrs. (Scale bar = 20 µm). 
Figure 6. Hypoxia-induced cell death is potentiated by knockdown of ang1. A, 
Quantitative real-time PCR analysis showing knockdown of endogenous murine ang1
by siRNA in NSC34 cells exposed to normoxia or 1% O2 for 24 hrs (*P<0.01 vs 
scramble, mean ± S.E.M. from 3 independent experiments). B-C, Nuclear
morphology in NSC34 motoneuron-like cells transfected with murine ang1 siRNA 
and exposed to 1% O2 for 24 (B) or 48 hrs (C) was assessed after Hoechst 33258 
staining. (*P<0.01 vs hypoxia-treated mock/scrambled cultures, mean ± S.E.M. from 
3 independent experiments). D, Nuclear morphology assessed by Hoechst 33258. 
Scale bar = 10 µm. 
Figure 7. Loss of neuroprotective activity against hypoxia of ALS-related ANG
mutations. A, Western blot analysis showing DsRed2 and human ANG levels in 
NSC34 cells transiently transfected with pIRES-DsRed2 constructs alone or 
containing the different ANG mutants. B, NSC34 cells transiently transfected with 
pIRES2-DsRed2/K40I, R31K, K17I, Q12L, I46V or C39W ANG do not show a 
26
significantly different response to hypoxia (1% O2 for 48 hrs) than cells transfected 
with empty vector pIRES2-DsRed2. Nuclear morphology was assessed after Hoechst 
33258 staining. (*P<0.01 vs hypoxia-treated empty vector, mean ± S.E.M. from 3 
independent experiments). C, Representative photomicrographs of NSC34 cells 
transfected with empty vector pIRES2-DsRed2 or containing ANG or K40I ANG.
Nuclear morphology was assessed after Hoechst 33258 staining (Scale bar = 20 µm). 
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Group Measure P(0) P(+) P(++) P(+++)
Controls Median 0.06 0.17 0.44 0.32
S.D. 0.09 0.08 0.13 0.17
ALS Median 0.09 0.08 0.55 0.26
S.D. 0.07 0.11 0.23 0.19
p value >0.5 >0.5 >0.5 >0.5
P( ), proportion of anterior horn motoneurons showing 0, +, ++, or +++
staining intensity.
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